等待开盘 05-23 09:30:00 美东时间
+0.260
+0.46%
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
Barclays analyst Michael Lonegan maintains Fortis (NYSE:FTS) with a Overweight and lowers the price target from $62 to $61.
05-08 23:11
Despite erratic enforcement of blockades and contradicting operations in the St...
05-08 08:00
Fortis Inc. shareholders approved all items at their Annual Meeting, including electing 12 directors, appointing Deloitte LLP as auditors, and endorsing executive compensation. Directors received strong support, with over 96% approval for all nominees. The auditors were approved with 99.78% support, and the Say on Pay resolution passed with 95.15% approval. Fortis, a leading North American utility provider, reported 2025 revenue of $12 billion an...
05-07 18:45
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
On Wednesday, Fortis (NYSE:FTS) discussed first-quarter financial results durin...
05-06 21:47
Fortis press release (FTS): Q1 GAAP EPS of C$0.99. Capital expenditures of C$1.4 billion in the first quarter; C$5.6 billion annual capital plan on track. OutlookFortis continues to enhance shareholde...
05-06 18:04
Fortis (NYSE:FTS) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.69 by 4.35 percent. This is a 2.86 percent increase over earnings of $0.70 per share from the same period
05-06 18:04
Fortis Inc. reported first-quarter 2026 net earnings of $501 million, or $0.99 per common share, with capital expenditures of $1.4 billion, aligning with its $5.6 billion annual plan. Regulatory approvals for UNS Gas rate adjustments and progress on TEP's rate case highlight strong performance. Major capital projects, including ITC's Big Cedar Load Expansion and FortisBC Energy's Tilbury LNG Storage Expansion, are advancing. Credit ratings remain...
05-06 10:00
今日重点评级关注:Canaccord Genuity:维持Intellia Therapeutics"买入"评级,目标价从48美元升至58美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从7美元升至8美元
04-29 10:28